Results 201 to 210 of about 109,213 (308)

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

MiRNA-based drugs: challenges and delivery strategies. [PDF]

Appl Microbiol Biotechnol
Wang Z, Peng Y, Zhou H, Zhang M, Ju D, Chen Z.   +5 more
europepmc   +1 more source

In‐Tumor CRISPR‐Cas9 Knockout Screening and Novel Therapy Development for Malignant Transformation of Ovarian Teratoma

Cancer Science, EarlyView.
We conducted an in vivo genome‐wide CRISPR‐Cas9 knockout screen using MTMCT‐derived cells to identify genes essential for tumor growth. SOD1 emerged as a key therapeutic target, and its inhibition suppressed tumor proliferation by disrupting redox homeostasis, both in vitro and in PDX models. ABSTRACT Malignant transformation of mature cystic teratoma (
Satoshi Tamauchi, Kosuke Yoshida, Wang Xinyuan, Atsushi Nakagawa, Akira Yokoi, Nobuhisa Yoshikawa, Kaoru Niimi, Yusuke Yamamoto, Hiroaki Kajiyama   +8 more
wiley   +1 more source

Genomic Aberrations of Antisense Gene Transcripts in Head and Neck Cancer. [PDF]

Cells
Ye J, Abbang SM, Ng YK, Lui VWY.
europepmc   +1 more source

KRAB Zinc‐Finger Protein ZNF205 Promotes Hepatocellular Carcinoma via p53 Pathway Repression

Cancer Science, EarlyView.
ZNF205 functions as a critical oncogenic regulator in hepatocellular carcinoma (HCC), where it interacts with p53 and functionally suppresses its transcriptional activity by competitively inhibiting p53 binding to target gene promoters. This p53 inactivation mechanism critically contributes to tumor progression in HCC. ABSTRACT The tumor suppressor p53
Xiaofen Huang, Yingchuan Yang, Yuan Ma, Wei Hao, Jingzhuo Jin, Yue Ding, Yiming Zhang, Xiuyuan Zhang, Xinli Li, Qin Song, Jiaqi Liu, Bingxin Liu, Yuanjun Zhai, Chunling Zhao, Jin Wu, Chunyan Tian   +15 more
wiley   +1 more source

Morpholino-RNA duplex exhibits robust, sustained, and safe steric-block antisense activity by intracerebroventricular and intrathecal injection. [PDF]

Nat Commun
Yanagidaira M, Nagata T, Hasegawa J, Ishii T, Ebihara S, Nawa M, Yokota T.   +6 more
europepmc   +1 more source

Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER+HER2− Breast Cancer

Cell Proliferation, EarlyView.
We generated endocrine‐resistant BC cell lines and identified CLEC3A, PCDH10, and ST3GAL1 as key endocrine‐resistant genes. More importantly, we validated their role in mediating resistance through PI3K‐AKT signalling and developed a predictive ERS with strong clinical relevance.
Liqin Ping, Lewei Zhu, Nian Chen, Xikun Liu, Jirui Zhong, Xiaoqing Sun, Hailin Tang, Kaiming Zhang   +7 more
wiley   +1 more source

LCN2‐ACOD1 Signalling Affects the Post‐Injury Regeneration of Skeletal Muscle Through Mediating Ferroptosis

Cell Proliferation, EarlyView.
LCN2 mediates the suppression of C2C12 myoblast proliferation and myotube formation via erastin‐induced ferroptosis. Mechanistically, the LCN2‐ACOD1 axis regulates skeletal muscle growth via mitochondria‐associated ferroptosis, providing a theoretical basis for the prevention and therapy of muscle‐related diseases.
Xiaojing Hao, Hongwei Shi, Di Wu, Rui Liang, Tong Zhao, Wen Sun, Yue Wang, Xiuju Yu, Xiaomao Luo, Yi Yan, Jiayin Lu, Haidong Wang, Juan Wang   +12 more
wiley   +1 more source

Targeting rare splicing defects: Antisense oligonucleotides offer a therapeutic strategy in FRDA. [PDF]

Mol Ther Nucleic Acids
Kerkhof LMC, Buijsen RAM.
europepmc   +1 more source